Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute

Based on discoveries by Oxford Biomedica's Drs. Susan and Alan Kingsman and others, scientists are now able to safely use modified lentiviruses as vectors, which enable RNAi to be effectively utilized as a research tool to unlock the secrets of the genetic code. As stated in the Court's Order, the viral vector developed by the Kingsmans' is expected to be useful as a "smart bomb" to safely "deliver new genetic material into specific cells, such as cells that do not divide or that divide slowly," giving the delivery of genes that produce dopamine into a Parkinson's disease patient's brain cells, as an example.

Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute: Financial News - Yahoo! Finance

Cool movie = RAPID EYE MOVEMENT

On October 23rd, 2007 a cool indie movie, RAPID EYE MOVEMENT, will be officially released and available on DVD. This indie thriller is 90 minutes of fast paced excitement! It stars Kansas Carradine in her feature debut, (daughter of KILL BILL 1 and KILL BILL 2's David Carradine), along with Federic Vial, who is the star of the BMW Motorcycle Films. Just in time for Halloween, this film has received 3.5 out of 4 stars on HorrorYearBook.com. Dr. Royce Clemens is quoting as saying, “As it stands, RAPID EYE MOVEMENT is a very impressive work that shows great promise. And in the land of the timid, I was blown away by the film’s insistence upon itself and the Mad-Prophet zeal of Tuckman himself.”

The film was shot on a shoe string budget with the heart and soul of true indie filmmaking and will keep you entertained to the very twisted ending.

You can check out the trailer at:

http://store.yorkentertainment.com/pgcart.pga?product=YPD-1424

and buy your own copy at:

http://video.barnesandnoble.com/search/results.asp?quickSearchType=TTL&FRM=0&quickSearchText=rapid+eye+movement&z=y

If you can, please forward this to your friends to help with our grass roots effort to support indie films. Thank you and enjoy the show!

I am creating artificial life, declares US gene pioneer, Venter

MARK THIS DATE: A team of 20 top scientists assembled by Mr Venter, led by the Nobel laureate Hamilton Smith, has already constructed a synthetic chromosome, a feat of virtuoso bio-engineering never previously achieved. Using lab-made chemicals, they have painstakingly stitched together a chromosome that is 381 genes long and contains 580,000 base pairs of genetic code. The DNA sequence is based on the bacterium Mycoplasma genitalium which the team pared down to the bare essentials needed to support life, removing a fifth of its genetic make-up. The wholly synthetically reconstructed chromosome, which the team have christened Mycoplasma laboratorium, has been watermarked with inks for easy recognition. It is then transplanted into a living bacterial cell and in the final stage of the process it is expected to take control of the cell and in effect become a new life form. The team of scientists has already successfully transplanted the genome of one type of bacterium into the cell of another, effectively changing the cell's species. Mr Venter said he was "100% confident" the same technique would work for the artificially created chromosome

I am creating artificial life, declares US gene pioneer Science The Guardian

Computers Boost Antibody-Based Drugs

Developing antibody-based drugs is a complex and time-consuming process. Scientists harvest antibodies from mice that have been injected with the target antigen. They then try to optimize the molecules by growing them in yeast and searching for random mutations that make the antibody bind to its target more tightly.

A computer program developed at MIT could vastly improve the design of antibody drugs. The software identified improvements in the anticancer drug cetuximab that increased its binding affinity by a factor of 10 in subsequent laboratory tests--a change that could lead to lower drug dosages and increased drug efficacy.


Technology Review: Computers Boost Antibody-Based Drugs